KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Other financing activities (2016 - 2026)

Gsk has reported Other financing activities over the past 18 years, most recently at $2.1 billion for Q1 2026.

  • For Q1 2026, Other financing activities rose 5954.02% year-over-year to $2.1 billion; the TTM value through Mar 2026 reached $2.1 billion, up 6090.42%, while the annual FY2025 figure was $61.2 million, 63.04% down from the prior year.
  • Other financing activities for Q1 2026 was $2.1 billion at Gsk, up from -$22.6 million in the prior quarter.
  • Over five years, Other financing activities peaked at $2.1 billion in Q1 2026 and troughed at -$36.5 million in Q1 2025.
  • A 5-year average of $184.9 million and a median of -$547437.9 in 2022 define the central range for Other financing activities.
  • Biggest five-year swings in Other financing activities: crashed 417.07% in 2025 and later skyrocketed 5954.02% in 2026.
  • Year by year, Other financing activities stood at $424.6 million in 2022, then decreased by 4.41% to $405.9 million in 2023, then crashed by 102.53% to -$10.3 million in 2024, then tumbled by 120.23% to -$22.6 million in 2025, then soared by 9555.74% to $2.1 billion in 2026.
  • Business Quant data shows Other financing activities for GSK at $2.1 billion in Q1 2026, -$22.6 million in Q4 2025, and -$6.7 million in Q3 2025.